On 16 July 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 70/2024 on the evaluation of the drug Opdivo (nivolumab) in combination with cabozantinib under the drug program “Treatment of patients with renal cell carcinoma (ICD-10: C64)”